The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2003-07-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1537685100PMID 12853564PMCID PMC166416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

  2002cited by this paper
• Smart drugs: tyrosine kinase inhibitors in cancer therapy.

  2002cited by this paper
• Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2

  2002cited by this paper
• Inhibition of protein kinase B/Akt. implications for cancer therapy.

  2002cited by this paper
• Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.

  2002cited by this paper
• Engineering polydactyl zinc-finger transcription factors

  2002cited by this paper
• Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

  2002cited by this paper
• Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.

  2002cited by this paper
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

  2002cited by this paper
• The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Tyrosine kinase inhibitors: From rational design to clinical trials

  2001cited by this paper
• Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.

  2001cited by this paper
• The EGF receptor family as targets for cancer therapy

  2000cited by this paper
• Positive and negative regulation of endogenous genes by designed transcription factors.

  2000cited by this paper
• Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells

  2000cited by this paper
• Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.

  2000cited by this paper
• ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency

  2000cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

  1999cited by this paper
• PIK3CA is implicated as an oncogene in ovarian cancer

  1999cited by this paper
• A Packaging Cell Line for Lentivirus Vectors

  1999cited by this paper
• The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.

  1999cited by this paper
• Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein.

  1998cited by this paper
• Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer.

  1998cited by this paper
• Expression of c-erbB3 protein in primary breast carcinomas.

  1998cited by this paper
• The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system.

  1998cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.

  1997cited by this paper
• Role of Translocation in the Activation and Function of Protein Kinase B*

  1997cited by this paper
• Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

  1996cited by this paper
• The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses

  1996cited by this paper
• A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

  1996cited by this paper
• Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

  1995cited by this paper
• Requirement for neuregulin receptor erbB2 in neural and cardiac development

  1995cited by this paper
• Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.

  1995cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling

  1995cited by this paper
• Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

  1995cited by this paper
• The cellular response to neuregulins is governed by complex interactions of the erbB receptor family

  1995cited by this paper
• Intracellular expression of single chain antibodies reverts ErbB-2 transformation.

  1994cited by this paper
• Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera.

  1994cited by this paper
• Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.

  1994cited by this paper
• Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members

  1994cited by this paper
• The biology of erbB-2/neu/HER-2 and its role in cancer.

  1994cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Cardioprotective Role of Neuregulin1-ErbB2 Signaling Pathway: Its Physiological and Onco-Cardiological Roles in the Heart.

  2026cites this paper
• Building a dynamic model for EGFR-family dimerization using quantitative, live-cell fluorescence methods.

  2025cites this paper
• LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis

  2025cites this paper
• Discovering anticancer drug target combinations via network-informed signaling-based approach

  2025cites this paper
• Small-molecule-induced ERBB4 activation to treat heart failure

  2025cites this paper
• Discovery of CZY43 as a new small-molecule degrader of pseudokinase HER3.

  2025cites this paper
• Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing

  2025cites this paper
• HER2, HER3 and mismatch repair protein expression in stage IV small bowel adenocarcinoma: results from a multicenter series.

  2025cites this paper
• Exploring the Conformational Landscape of Complexes with Cucurbit[8]uril and Aromatic Peptide Dimers by Ion Mobility Mass Spectrometry and Theoretical Calculations.

  2025cites this paper
• Novel Humanized Anti-HER3 Antibodies: Structural Characterization and Therapeutic Activity

  2025cites this paper
• Exploring vulnerable building blocks in protein-protein interaction networks of breast tumor and adjacent normal tissues

  2025cites this paper
• Synthesis, Crystallographic study, in silico and in vitro investigation of novel flavonol-amino acid conjugate as an anti-proliferative agent

  2025cites this paper
• Emerging importance of HER3 in tumorigenesis and cancer therapy

  2025cites this paper
• Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma

  2025cites this paper
• Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer

  2025cites this paper
• Structural analysis of HER2-trastuzumab complex reveals receptor conformational adaptation

  2025cites this paper
• Trans-activating mutations of the pseudokinase ERBB3

  2024cites this paper
• CAR-T cells are more affected than T lymphocytes by mechanical constraints: A microfluidic-based approach.

  2024cites this paper
• HER3 receptor and its role in the therapeutic management of metastatic breast cancer

  2024cites this paper
• LRG1 promotes metastatic colorectal cancer growth through HER3 signaling.

  2024cites this paper
• Targeting FTO suppresses hepatocellular carcinoma by inhibiting ERBB3 and TUBB4A expression.

  2024cites this paper
• Antitumor activity of PAbs generated by immunization with a novel HER3-targeting protein-based vaccine candidate in preclinical models

  2024cites this paper
• Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy

  2024cites this paper
• A review of recombinant HER3 affibodies with an effective diagnostic view of cancer cells

  2024cites this paper
• HER3: Updates and current biology function, targeted therapy and pathologic detecting methods.

  2024cites this paper
• miR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer

  2024cites this paper
• Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes.

  2024cites this paper
• Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

  2024cites this paper
• Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer

  2024cites this paper
• The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer

  2024cites this paper
• The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs)

  2024cites this paper
• HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future

  2024cites this paper
• PI3K Mutation Profiles on Exons 9 (E545K and E542K) and 20 (H1047R) in Mexican Patients With HER-2 Overexpressed Breast Cancer and Its Relevance on Clinical–Pathological and Survival Biological Effects

  2024cites this paper
• Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

  2024cites this paper
• Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery

  2024cites this paper
• A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup ATRTs.

  2024cites this paper
• ERBB3 Targeting: A Promising Approach to Overcoming Cancer Therapeutic Resistance.

  2024cites this paper
• Conventional and Advanced Therapeutic Approaches in Breast Cancer Treatment

  2023cites this paper
• Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease

  2023cites this paper
• Characterization of Expression and Function of the Formins FHOD1, INF2, and DAAM1 in HER2-Positive Breast Cancer

  2023cites this paper
• Breast Cancer Associated Conventional and Advanced Therapies 

  2023cites this paper
• Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

  2023cites this paper
• To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors.

  2023cites this paper
• Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA

  2023cites this paper
• Common hotspots of cancer chemotherapy

  2023cites this paper
• Bioinformatics and Next-Generation Data Analysis for Identification of Genes and Molecular Pathways Involved in Subjects with Diabetes and Obesity

  2023cites this paper
• Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression

  2023cites this paper
• Desmocollin-1 is associated with pro-metastatic phenotype of luminal A breast cancer cells and is modulated by parthenolide

  2023cites this paper
• Gut barrier-microbiota imbalances in early life lead to higher sensitivity to inflammation in a murine model of C-section delivery

  2023cites this paper
• Single-cell and spatial transcriptome analysis reveals the cellular heterogeneity of liver metastatic colorectal cancer

  2023cites this paper
• Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy

  2023cites this paper
• Engineered synthetic nanobody-based biosensors for electrochemical detection of epidermal growth factor receptor

  2023cites this paper
• Research Progress of Targeted Combined Immunization in HER2 Positive Advanced Gastric Cancer: From Bench to Bedside

  2023cites this paper
• Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

  2023cites this paper
• HER3-targeted therapeutic antibodies and antibody–drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors

  2023cites this paper
• A Chinese Medicine, Huajie Xiaoliu Formula, Enhances the Anti-Colon Cancer Effect of Tegafur, Gimeracil, and Oteracil Potassium Capsules Through Bcl-2/Bax Signaling Pathway

  2023cites this paper
• An unanticipated discourse of HB-EGF with VANGL2 signaling during embryo implantation

  2023cites this paper
• CD98 regulates the phosphorylation of HER2 and a bispecific anti‐HER2/CD98 antibody inhibits the growth signal of human breast cancer cells

  2023cites this paper
• Coordinate transcriptional regulation of ErbB2/3 by C-terminal binding protein 2 signals sensitivity to ErbB2 inhibition in pancreatic adenocarcinoma

  2023cites this paper
• Cancer immune exclusion: breaking the barricade for a successful immunotherapy

  2023cites this paper
• HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer

  2023cites this paper
• ERBB Receptors and Their Ligands in the Developing Mammary Glands of Different Species: Fifteen Characters in Search of an Author

  2023cites this paper
• Discoidin domain receptor 1 regulates ErbB2/ErbB3 signaling in mammary epithelial cells

  2022cites this paper
• Targeting HER2-positive breast cancer: advances and future directions

  2022cites this paper
• Possible Involvement of the Upregulation of ΔNp63 Expression Mediated by HER2-Activated Aryl Hydrocarbon Receptor in Mammosphere Maintenance

  2022influential citation
• Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.

  2022cites this paper
• PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer

  2022cites this paper
• Molecular characterization of ESR1 variants in breast cancer

  2022cites this paper
• HER3 in cancer: from the bench to the bedside

  2022cites this paper
• Cell Proliferation Receptor-Enhanced 3D High-Throughput Screening Model for Optimized Drug Efficacy Evaluation in Breast Cancer Cells.

  2022cites this paper
• PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer

  2022cites this paper
• Machine Learning-Devised Immune-Related lncRNA Signature Panel Predicts the Prognosis and Immune Landscape in Breast Cancer Novel IRLP Signature in BRCA

  2022cites this paper
• Network Pharmacology Analysis, Molecular Docking, and In Vitro Verification Reveal the Action Mechanism of Prunella vulgaris L. in Treating Breast Cancer

  2022cites this paper
• Improved prediction of gene expression through integrating cell signalling models with machine learning

  2022cites this paper
• Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models

  2022cites this paper
• ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells

  2022cites this paper
• Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK

  2022cites this paper
• An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next

  2022cites this paper
• The molecular, immune features, and risk score construction of intraductal papillary mucinous neoplasm patients

  2022cites this paper
• Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions

  2022cites this paper
• Cascade Downregulation of the HER Family by a Dual‐Targeted Recombinant Protein–Drug Conjugate to Inhibit Tumor Growth and Metastasis

  2022cites this paper
• Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies

  2022cites this paper
• Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.

  2022cites this paper
• Time-extended exposure of gastric epithelial cells to secretome of Helicobacter pylori-activated fibroblasts induces reprogramming of gastric epithelium towards pre-cancerogenic and pro-invasive phenotype.

  2022cites this paper
• Novel cell lines derived from Chinese hamster kidney tissue

  2022influential citation
• Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications

  2022cites this paper
• ERBB Signaling Pathway in Cancer Stem Cells.

  2022cites this paper
• Molecular Pathways and Mechanisms of HER2 in Cancer Therapy.

  2022cites this paper
• NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells

  2022cites this paper
• Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?

  2022cites this paper
• The significance of ErbB2/3 in the conversion of induced pluripotent stem cells into cancer stem cells

  2022cites this paper
• miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy

  2022cites this paper
• A recombinant affitoxin derived from a HER3 affibody and diphteria-toxin has potent and selective antitumor activity.

  2022cites this paper
• Triple targeting of HER receptors overcomes heregulin-mediated resistance to EGFR blockade in colorectal cancer.

  2022cites this paper
• Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

  2022cites this paper
• Piper betle stem extract induces apoptosis through mitochondria inactivation, p38MAPK activation and ErB2/ErbB3 suppression on oral squamous cell carcinoma cells

  2022cites this paper
• Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum.

  2022cites this paper
• Fusion‐associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance

  2022cites this paper
• Breast Cancer Stem Cell Membrane Biomarkers: Therapy Targeting and Clinical Implications

  2022cites this paper
• Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers

  2022cites this paper